MedTrace Logo

A Study of A4368 in Healthy Subjects

NCT04932252 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2023-01-18

No results posted yet for this study

Summary

A4368 is the autophagy activator that is being developed for the treatment of nonalcoholic steatohepatitis.

The goal of the study is to assess the safety, tolerability, and pharmacokinetics in healthy subjects.

Conditions

  • Health Subjects

Interventions

DRUG

A4368 or placebo tablet

orally administered

Sponsors & Collaborators

  • Autophagy Sciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Seunghoon Han · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2022-07-25
Completion
2022-07-25

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04932252 on ClinicalTrials.gov